Background-Use of pretest probability can reduce unnecessary testing. We hypothesize that quantitative pretest probability, linked to evidence-based management strategies, can reduce unnecessary radiation exposure and cost in low-risk patients with symptoms suggestive of acute coronary syndrome and pulmonary embolism. Methods and Results-This was a prospective, 4-center, randomized controlled trial of decision support effectiveness.
I n emergency care, clinicians commonly order tests that suggest inclusion of both acute coronary syndrome (ACS) and pulmonary embolism (PE) on their differential diagnosis list for individual patients. 1 Because both ACS and PE can cause sudden death, the perception of medicolegal risk, and normative social influence, many clinicians apply a liberal policy for diagnostic testing for these diseases. 2, 3 Overuse of diagnostic testing can harm patients with low risk by exposing them to unnecessary medical radiation, intravenous contrast, economic cost, and adverse effects from treatments prescribed for ambiguous diagnostic test results. [4] [5] [6] National agencies have advocated computerized decision support aids to improve the diagnosis and management of patients with chest pain and shortness of breath. 7 Randomized trials have demonstrated variable effects of computerized decision support on test ordering for patients with possible ACS or PE, but no study has addressed both diagnoses simultaneously. [8] [9] [10] [11] Clinical Perspective on p 73
The present multicenter, randomized trial tests the effectiveness of a Web-based computer program that provides quantitative pretest probability for patients with symptoms suggesting both ACS and PE. In addition to simultaneously addressing 2 potential diagnoses, another novel aspect of this decision support includes the presentation of a management strategy, designed to minimize radiation exposure, while using a Bayesian approach to maintain a posterior probability of both ACS and PE <1%. 12, 13 We hypothesized that disclosure of this intervention would reduce the proportion of patients unnecessarily exposed to excessive radiation doses while reducing cost for medical care without increasing the rate of delayed diagnosis, adverse events, or need to return for hospital care.
Methods

Overall Design
This was a multicenter, 2-phase clinical trial conducted at 3 academic emergency departments and 1 community hospital. The methods have been described in more detail previously. 1 The first phase was a noninterventional pilot study of 300 patients designed to test the accuracy of the webtool used to calculate pretest probability and to pilot test the study methodology followed by an interventional phase. The interventional phase was a randomized, nonblinded clinical trial. The study was registered (NCT1059500).
The study was approved by the Institutional Review Boards at all sites; study participants were clinicians and patients who both provided informed consent to participate. Patients were adults (aged >17 years) who presented to the emergency department with a chief complaint of chest pain and new or worsened shortness of breath or breathing difficulty documented by a clinician in the written history of present illness or review of systems. Patients had a nondiagnostic 12-lead ECG, defined as the absence of any suggestion of ischemia or infarction on the computer interpretation printed on the top of the ECG. Exclusion criteria are listed in the Figure. The decision support system used in this work is a computerized method that produces a quantitative estimate of pretest probability from the method of attribute matching, run from an internet-based platform referred to as the webtool, demonstrated in the Figure in the onlineonly Data Supplement. 14 The webtool can be operated from the following addresses: for ACS, http://pretestconsult.com/v21/acs; and for acute PE, http://pretestconsult.com/v21/pe. The webtool required 17 unique predictor variables for each patient (step 2, Figure in the onlineonly Data Supplement), which were input and verified by the clinician (step 3, Figure in the Data Supplement). Before receiving any output from the webtool, the clinician recorded these variables on a paper case report form, together with his or her implicit estimate pretest probability of each condition, marked on a 10-cm visual analogue scale. The purpose of assessing this implicit estimate was to measure strength of correlation and agreement between the clinician's beliefs and the webtool. 15 The U.S. Food and Drug Administration requirements for proceeding from the pilot to the intervention trial were as follows: first, that ≥20% of the pilot sample of participants have both ACS and PE pretest probability assessments <2.5%; and second, that observed ACS and PE rates in this subgroup were <1.0%.
In the interventional phase, for each patient, the webtool then used the SQL random number generator function [rand()] to generate a
Figure.
Flow diagram and outcomes of enrolled patients. ACS indicates acute coronary syndrome; AMI, acute myocardial infarction; ECG, electrocardiogram; ED, emergency department; I/E, inclusion and exclusion; PE, pulmonary embolism; and SBP, systolic blood pressure. 0 or 1, which assigned the patient and clinician to either the control or intervention group. The control group received a message saying, "Sham assignment, no additional information will be provided." The intervention group received estimates of the pretest probabilities derived from attribute matching models that have been previously validated (see step 4, Figure in the Data Supplement). 10, 11, 14, 16, 17 The pretest probability range was divided into 4 tiers for each condition. Each pretest probability was accompanied on the same screen by a tier-specific, recommended diagnostic strategy, designed using a Bayesian approach to produce a posterior probability <1%, while minimizing radiation dose, cost, and time required for evaluation. 13 This screen was printed and entered into the paper medical record (step 5, Figure in the Data Supplement). Clinicians in the intervention group had to then answer yes, no, or maybe in response to the question of whether they planned to use the results of the webtool. Research assistants made no advisory comments to the clinician or patient and did not show the results to anyone other than the treating clinician. The clinician could share the information with the patient at his or her discretion. Because of anticipated problems associated with determining the timing and authorship of orders in the emergency department setting, we did not plan formal methods to assess clinician participant adherence to recommended guidelines.
Clinical data were collected, and criterion standards were defined in accordance with the Standards for Reporting Diagnostic Accuracy initiative and published methodology standards for emergency care research studying ACS and PE. 13, 18 Research assistants contacted all patients at 90 days by telephone to administer a validated questionnaire to assess for outcomes, and patient responses were supplemented by structured review of each hospital's comprehensive electronic medical record database. 19 Significant cardiopulmonary diagnoses were ACS, PE, aortic dissection or aneurysm, pneumothorax, arrhythmia requiring intravenous medication, pneumonia, heart failure, pericarditis/myocarditis, severe asthma or other lung disease requiring hospitalization, mediastinal mass, and sepsis. Methods for criterion standards are described in the Data Supplement. We defined adverse events according to Good Clinical Practice standards (any death, allergic reaction, or event requiring prolongation or unexpected hospitalization, or the initiation of new treatment). All outcomes, including determination of delay in diagnosis, were determined from an adjudication process in which 2 researchers, blinded to group assignment, independently determined whether the subject had ACS or PE using the criterion standard definitions. 16, 19 If a patient verbally reported diagnosis of ACS or PE on telephone follow-up, this report was confirmed by the medical record.
Radiation dosimetry was calculated with attention to expert guidelines that were published at the time the protocol was initiated. 20, 21 For computerized tomography (CT) scanning, we recorded the dose length product to assess external dose, but because this does not account for radiation from nuclear scans, fluoroscopy, or plain film radiology, we used a fixed estimated millisievert dose per examination using published tables for the main outcome measurement of effective radiation dose. 21 Patient satisfaction was assessed 2 to 4 weeks after enrollment by a scripted survey delivered by trained observers who were blinded to the patient's study group assignment. The survey asked questions used by commercial entities (eg, Press-Ganey) to assess customer satisfaction of emergency department patients. 1 Medical costs for all materials and services, regardless of reason (ie, not restricted to evaluation or treatment of cardiopulmonary disease), were assessed for 30 days postenrollment from line item analysis of costs for intensive care services, imaging, pharmacy, laboratory, respiratory, and other service groupings in the universal hospital claims submission form (UB-92 CMS-1450), commonly called the UB-92. 22 These data exclude professional billing and were obtained from reports generated by the local databases used for patient billing in each hospital's accounting department.
The sample size was predicated on the hypothesis that the intervention would reduce unnecessary exposure to a significant dose of radiation. This primary outcome was defined as a patient exposed to >5 mSv estimated effective radiation to the chest who went on to have no significant cardiopulmonary diagnosis on 90-day follow-up. Based on prior work, we estimated that the intervention would reduce the proportion of patients with unnecessary exposure to an effective dose >5 mSv to the chest from 25% in the control group to 15% in the intervention group. 11 With this assumption and α=0.05 and β=0.20, we estimated that a sample size of 550 patients would produce an exact 2-sided P<0.05. Proportions were compared using 95% confidence intervals (CIs) for the difference and the 2-sided P value from the exact test of independent proportions. Secondary but interdependent measurements included the cumulative estimated effective dose of radiation in millisieverts, cost and charge of care, length of stay (in the emergency department and hospital), and patient satisfaction, which were compared between groups with a Mann-Whitney U test. To account for clustering effect of enrolling the same physician more than once, we used mixed effects models to account for within physician clustering. Specifically, for binary outcomes, we used the SAS proc PROC GLIMMIX to perform a mixed effects logistic regression with a fixed effect for intervention and random effect for physician to account for correlation within physician. Similarly, for continuous outcomes, we used PROC MIXED with a fixed effect for intervention and random effect for physician. The log transform was used for the main continuous outcome measures attributable to the skewness of the data. Correlation and agreement between the Web-based method and clinician estimate of pretest probability was tested with Spearman rank correlation and McNemar exact statistic. Statistical analyses were performed using commercial software (StatsDirect, v 2.7.98, Cheshire, England, and SAS version 9.3, Cary, NC).
Results
The pilot study of 300 patients was conducted from January to December 2010 at all 4 sites. In this noninterventional phase, 73 (24%) and 140 (47%) patients had a pretest probability estimate for PE and ACS, respectively, of <2.5%. None of these patients had a diagnosis of PE or ACS within 90 days, thus meeting the predefined requirement for diagnostic accuracy. Patients were enrolled in the randomized trial phase from July 2011 to May 2012. The Figure shows the study design and outcomes of all patients. We obtained complete data on 541 patients, including 277 randomized to control and 264 randomized to the intervention. Table 1 presents the clinical features of the patient population, stratified by treatment group. Syncope and connective tissue diseases were observed more often in the intervention group, but the groups were otherwise well matched. Logistic regression analysis showed that neither of these variables was significantly associated with the primary outcome. The distribution of pretest probabilities according to the predefined tiers, the number of patients diagnosed with ACS and PE within 90 days, and the recommended clinical actions for each tier of pretest probability is shown in Table 2 . One hundred sixty-four (30%) of patients had pretest probability estimates <2.5% for both ACS and PE. Clinician participants included 270 unique clinicians. One hundred twenty-three clinicians were enrolled only once; 24 were enrolled ≥5 times (median number of enrollments=1; first-third quartiles, 1-2; range, 1-11). Three clinicians were enrolled >10 times.
The main results are shown in Table 3 . The table shows medians because all data were non-normally distributed. Randomization to the intervention group was associated with lower radiation exposure to the chest, lower in-hospital length of stay, and lower charges and estimated costs for medical care within 90 days of initial emergency department presentation. Regarding the primary outcome, the median radiation dose and the proportion with >5 mSv to the chest was also reduced in the subset of patients with no ACS, no PE, and no other significant cardiopulmonary diagnosis within 90 days: 91 of 277 (33%) in controls versus 66 of 264 (25%) in the intervention group, P=0.038, exact binomial test, 95% CI for the difference of 8%: 0.2% to 15.4%. Using PROC GLIMMIX for the same comparison, P=0.047 (odds ratio=0.68; 95% CI, 0.47-0.99). In the intervention group, the distributions of clinicians' responses of yes, no, or maybe regarding their plan to use the results were similar between ACS (yes=56%; no=27%; maybe=17%) and PE (yes=59%; no=24%; maybe=17%). However, we found no significant differences in median values of radiation dose, cost, charge, or length of stay between clinicians who answered yes versus those who answered no. We examined for potential effect of clinician experience by comparing the results of 1-time clinician participants (n=127 clinicians) with those who participated ≥5 times (n=24 clinicians). First, regarding their stated intent to use the device when randomized to device, single-time participants indicated intent to use the recommendation in 32 of 85 (38%) instances, whereas ≥5-time participants indicated intent to use the recommendation in 46 of 89 (52%) instances (95% CI for difference of 14%, 0.1%-28%; P=0.051). Second, we compared the main outcome variables, namely, radiation exposure to the chest and cost data. Median radiation exposure of patients cared for by 1-time participants was 0.85 mSv (first-third quartiles, 0.06-8.08 mSv) versus 0.12 mSv (0.06-8.06 mSv) for ≥5-time participants (P=0.54, Mann-Whitney U test), and the median cost of medical care provided by 1-time participants was $1031 ($612-$2073) versus $1188 ($587-$2985) for ≥5-time participants (P=0.32). These data suggest a slight trend toward increased effectiveness with serial use.
The single largest source of radiation to the chest was CT pulmonary angiography, accounting for 46% of all radiation. However, reductions in radiation exposure in the intervention group occurred as a result of across the board incremental reductions in ordering of tests that use radiation, as opposed to preventing any 1 imaging study. Specifically, the control group tended to undergo more cardiac catheterizations (6% versus 3% for intervention patients), cardiac nuclear studies (16% versus 11%), CT pulmonary angiography (29% versus 20%), and ≥1 CT imaging study of the torso or neck, exclusive of the head (42% versus 38%). The mean cumulative dose length product from patients who underwent CT scanning of the torso or neck was 722±628 mGy-cm in controls versus 660±424 mGy-cm in the intervention group (P=0.45), with a range of 0 to 5535 mGy-cm. We did not record the dose length product specific to imaging of the chest.
Among patients with the lowest tier of pretest probability, a larger fraction in the intervention group underwent no disease-specific diagnostic testing, as was recommended by the webtool. For ACS pretest probabilities <2.5%, no diagnostic test for ACS (other than the study required initial 12-lead ECG) was ordered in 53 of 137 (39%) of the intervention group, compared with 36 of 149 (24%) of the sham group (P=0.007; 95% CI for the difference of 15%, 4%-25%). For PE pretest probabilities <2.5%, no diagnostic test for PE was ordered in 66 of 101 (65%) of the intervention group, compared with 48 of 95 (51%) of the sham group (P=0.03; 95% CI for the difference of 14%, 10%-28%). Table 4 presents data to assess safety of the intervention. The combined frequency of diagnosis of ACS and PE within 90 days tended to be lower in the intervention group (3.8%) than the control group (6.8%), but this did not reach statistical significance (P=0.09; 95% CI for the difference of 3.0%, 0%-7.1%). One patient in the intervention group had the diagnosis of ACS delayed by >12 hours, and 1 patient control group had the diagnosis of PE delayed by >12 hours. Both of these patients were alive and reported their general state of health as better at 90 days. We found no significant difference in the proportion of patients who were discharged from the emergency department (45.6% for intervention versus 44.4% for control; 95% CI for difference, −7.3% to 9.4%), the rate of return for care to an emergency department with or without hospitalization, or the occurrence of adverse events. Table I in the Data Supplement compares how often the clinician and the webtool agreed on pretest probability according to the 4 predefined tiers. The clinicians and the webtool had a high rate of discordance, seldom categorizing patients within the same pretest probability tier, such that the overall agreement was only 35% for ACS and 31% for PE. Clinicians had consistently higher pretest probability estimates compared with the validated webtool. Spearman rank test revealed ρ=0.45 (95% CI, 0.38-0.51) for ACS and ρ=0.21 (95% CI, 0.13-0.29) for PE. These data suggest that the webtool was not simply reinforcing existing beliefs. When the matched pairs (clinician estimate and webtool) were stratified into categories of pretest probability in Table I in the Data Supplement, the estimations for all categories were significantly different except for the moderate category (2.5%-5.5%) for ACS.
The results of the patient satisfaction survey are shown in Table II in the Data Supplement. The best total score a patient could give was 6, and the worst was 30. The values for the total score for intervention patients (median=9; interquartile range, [6] [7] [8] [9] [10] [11] [12] [13] [14] were not significantly different from that of controls (median=10; interquartile range, 6-14; P=0.148).
Discussion
We found that patients who were randomized to a decision support intervention that provided their clinicians with pretest probabilities and risk-tailored management suggestions had lower exposure to medical radiation to the chest, lower cost of medical care, and no increase in adverse events for the subsequent 90 days compared with patients in the control (usual care) group. The present study provides 3 novel features of the design and implementation of decision support that are particularly relevant to imaging of high-risk patients in the emergency care environment. [8] [9] [10] [11] First, we address the fact that emergency care demands that clinicians exclude, with a reasonable degree of medical certainty, all threats to life on their active differential diagnosis list. ACS and PE often appear together on the active differential diagnosis list for the same patient, and emergency clinicians are keenly aware that these 2 diseases are the leading causes of sudden unexpected death in adults. 23, 24 This combination of influences may contribute to overtesting of patients with symptoms of ACS and PE, particularly with the use of CT imaging. 25 Accordingly, we tested a computerized clinical support system that provided pretest probability estimates for both ACS and PE in patients who have symptoms of both. Second, we presented the pretest probability estimates with recommended explicit clinical actions. Third, we tested this system in a multicenter, randomized trial according to a predefined, registered, and externally monitored protocol.
We believe this is the first study to demonstrate direct benefit of an electronic decision support system to help resolve decisional conflict for patients who present with symptoms suggesting >1 potential cogent diagnosis. 26 The study design was thus particularly relevant to emergency care, which often involves simultaneously weighing the relative likelihoods of >1 disease that if untreated can cause rapid death. For patients with chest pain and dyspnea, the remote possibility of failing to diagnose ACS or PE, the specter of the patient's death, and concern for possible allegation of negligence compel many emergency clinicians in the United States to order diagnostic tests at exceedingly low pretest probabilities.
The benefits of randomization to receiving the output of the instrument were striking. These included a relative reduction of 27% in the cost of medical care measured up to 30 days after enrollment and reduction of median radiation exposure to the chest by one fourth, measured out to 90 days postenrollment. Similar relative differences were observed for mean values. The reduction in radiation was the net result of incremental reductions in both pulmonary vascular and cardiac imaging, suggesting effectiveness of providing 2 pretest probability estimates. Although patients in the intervention group generally had fewer tests and less imaging exposure, this reduction in testing prompted neither an increased rate of return to the hospital nor an increase in all-cause adverse events. In both groups, only 1 patient had delayed diagnosis, including ACS in the intervention group and 1 with PE in the control group. Both patients were admitted, both had their diagnoses delayed until the fourth day after presentation to the emergency department, and both had good outcomes. We also present data that show the effect size was not driven by an inordinate contribution of a few clinicians.
Limitations include that we found no improvement in patient satisfaction with the intervention. The fact that intervention patients underwent less diagnostic testing in the absence of a shared decision-making design may explain this finding. Marple et al 27 found that patient residual desire for diagnostic tests was a key determinant of patients being less than fully satisfied with their medical care. We think that patient satisfaction of the explanation of their condition would have been improved had we used a shared decision-making design as we have done previously. 10, 11 A coronary calcium score of 0 may miss noncalcified coronary lesions, but its use was justified based on an estimated likelihood ratio of <0.20 from a published meta-analysis and the results of an emergency department-based management protocol and the findings of our pilot study. 28, 29 The sole patient with delayed diagnosis of ACS had a coronary calcium score of 0, but had an elevated troponin measurement that prompted cardiac catheterization, which demonstrated a muscular bridge lesion, which was treated medically.
Conclusions
This study demonstrates that single use of a Web-based, clinical support instrument that provided a quantitative pretest probability estimate for both ACS and PE in symptomatic emergency department patients, linked to management recommendations, produced significant and lasting reductions in exposure to medical radiation and cost of medical care. Those designing computer-based decision support interventions in emergency care for clinical presentations that raise a predictable differential diagnosis should consider providing quantitative assessment of risk and recommended management strategies for >1 diagnosis.
